Genenta Science S.p.A. (SAEN) stock

SAENNasdaqBiological Products, (No Diagnostic Substances)Also trades as GNTA

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30

$0.68−0.04 (-5.28%)

Close on Nov 11, 2026Market cap $15.93MP/E –Yield –

Genenta Science S.p.A. statistics

51 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Dec 31, 2025
Share price as of: –

Valuation ratiosIndustry

Market Cap: €14.29M; €804.14M
Enterprise Value: -€13.86M; €571.68M
PB Ratio: 0.65; 0.66
P/TBV Ratio: 0.65; 1.28

Share statisticsIndustry

Shares Outstanding: 23M; 100M
Shares Change (YoY): 7.86%; 5.61%
Float: 16M; 79M
Shares Held by Insiders: 33.5%; 9.05%
Shares Held by Institutions: 3.08%; 20.8%

Stock price statisticsIndustry

Price Change (1 Week): -2.86%; 2.02%
Price Change (1 Month): -5.82%; 8.16%
Price Change (3 Months): -47.7%; -13.7%
Price Change (6 Months): 15.9%; -4.97%
Price Change (YTD): -54.4%; -8.54%
Price Change (1 Year): -69.1%; -15.2%
Price Change (3 Years): -87.4%; -7.58%
Average Volume (10 Days): 265,570; –
Average Volume (20 Days): 152,134; –
Average Volume (90 Days): 81,507; –
Relative Volume: 0.10; 0.70
Relative Strength Index (14): 47.8; 55.5
Volatility (1 Year): 130.9%; 65.1%
Beta (5 Years): 0.26; 0.87

Returns on capitalIndustry

Return on Equity (ROE): -38.0%; -15.4%
Return on Assets (ROA): -28.0%; -1.57%
Return on Capital Employed (ROCE): -22.2%; -23.8%

Financial positionIndustry

Current Ratio: 14.16; 3.49
Quick Ratio: 13.29; 1.51

EfficiencyIndustry

Profits Per Employee: -€502.29K; -€43.26K
Employee Count: 13; 304
WACC: 7.38%; 9.37%

Income statement (TTM)Industry

Operating Income: -€6.60M; -€54.01M
Pretax Income: -€6.53M; -€47.40M
Net Income: -€6.53M; €157.18M
EBITDA: -€6.58M; -€42.85M
EPS (Diluted): -0.33 EUR; -0.55 EUR

Balance sheetIndustry

Cash & Short-Term Investments: €28.15M; €199.29M
Net Cash (Debt): €28.15M; €111.50M
Net Cash Per Share: 1.20 EUR; 1.53 EUR
Equity (Book Value): €21.84M; €472.30M
Book Value Per Share: 0.93 EUR; 6.00 EUR
Tangible Book Value: €21.84M; €50.66M
Working Capital: €27.86M; €119.55M

Cash flow (TTM)Industry

Operating Cash Flow: -€6.87M; -€42.16M
Capital Expenditures: -€7.63K; -€2.34M
Free Cash Flow: -€6.88M; -€52.90M
FCF Per Share: -0.29 EUR; -0.48 EUR

Dividends and yieldsIndustry

Earnings Yield: -45.7%; -1.68%
FCF Yield: -48.1%; -13.2%

Scores and fair valueIndustry

Altman Z-Score: -1.53; 1.20
Piotroski F-Score: 4; 5

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.

Period	SAEN	S&P 500	Difference	SAEN per year	S&P 500 per year
1 month	-13.4%	-2.4%	−11.0 pts
3 months	-47.7%	-1.2%	−46.5 pts
Year to date	-54.4%	+12.3%	−66.7 pts
1 year	-69.1%	+12.4%	−81.5 pts
3 years	-87.4%	+78.8%	−166.2 pts	-49.9%	+21.4%

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?